Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts

Luspatercept is an approved therapy for selected patients with lower risk myelodysplasia requiring transfusion despite erythropoiesis-stimulating agents, based on the early results of a randomized trial against placebo. Zeidan and colleagues report that after a median of 26 months follow-up, 27% of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeidan, Amer M., Platzbecker, Uwe, Garcia-Manero, Guillermo, Sekeres, Mikkael A., Fenaux, Pierre, DeZern, Amy E., Greenberg, Peter L., Savona, Michael R., Jurcic, Joseph G., Verma, Amit K., Mufti, Ghulam J., Buckstein, Rena, Santini, Valeria, Shetty, Jeevan K., Ito, Rodrigo, Zhang, Jennie, Zhang, George, Ha, Xianwei, Backstrom, Jay T., Komrokji, Rami S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Letter to Blood
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653038/
https://www.ncbi.nlm.nih.gov/pubmed/35797468
http://dx.doi.org/10.1182/blood.2022016171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653038/
https://www.ncbi.nlm.nih.gov/pubmed/35797468
http://dx.doi.org/10.1182/blood.2022016171

Ejemplares similares